Get the Stockscreener App
1.9601
7.98%
-0.1699
After Hours:
2.00
0.0399
+2.04%
Nucana Plc Adr stock is traded at $1.9601, with a volume of 58,715.
It is down -7.98% in the last 24 hours and down -6.22% over the past month.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
See More
Previous Close:
$2.13
Open:
$2.13
24h Volume:
58,715
Relative Volume:
0.98
Market Cap:
$8.16M
Revenue:
-
Net Income/Loss:
$-33.44M
P/E Ratio:
-0.1223
EPS:
-16.0242
Net Cash Flow:
$-28.30M
1W Performance:
-10.50%
1M Performance:
-6.22%
6M Performance:
-31.70%
1Y Performance:
-98.92%
1-Day Range:
$1.95
$2.22
1-Week Range:
$1.95
$2.22
52-Week Range:
$1.95
$268.00
Nucana Plc Adr Stock (NCNA) Company Profile
Compare NCNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NCNA
Nucana Plc Adr
|
1.9601 | 8.86M | 0 | -33.44M | -28.30M | -16.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-03-22 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-22-20 | Initiated | Truist | Buy |
| Jul-24-20 | Initiated | Oppenheimer | Outperform |
| Aug-19-19 | Initiated | H.C. Wainwright | Buy |
| Oct-19-18 | Initiated | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | Citigroup | Buy |
| Oct-23-17 | Initiated | Jefferies | Buy |
| Oct-23-17 | Initiated | William Blair | Outperform |
View All
Nucana Plc Adr Stock (NCNA) Latest News
Persistent bearish signals and technical resistance — NuCana stock drops 4.63% - Traders Union
NuCana sees a dip — What is pressuring the stock - Traders Union
NCNA Earnings History & Surprises | EPS & Revenue Results | NUCANA PLC-ADR (NASDAQ:NCNA) - ChartMill
NuCana stock price forecast: Bear signals weigh as NCNA dips beneath key levels - Traders Union
NCNA Fundamental Analysis | NUCANA PLC-ADR (NASDAQ:NCNA) - ChartMill
Weak technical signals and persistent selling — NuCana stock falls 4.02% - Traders Union
What is behind NuCana recent drop in value today - Traders Union
What triggered NuCana latest price surge - Traders Union
NuCana stock: persistent negative momentum drives 3.40% gain despite mixed technicals - Traders Union
NuCana climbs today: Key reasons behind the rally - Traders Union
Buying pressure lifts NuCana higher in today trading - Traders Union
NuCana slides today: Key reasons behind the decline - Traders Union
NuCana stock price forecast: Further downside risk as NCNA drops 3.75% near support levels - Traders Union
NuCana stock: Bearish trends and weak support drive continued price decline - Traders Union
Deeply oversold RSI and bearish technicals — NuCana stock gains 3% - Traders Union
-5.76% for NuCana stock — oversold levels signal persistent bearish pressure - Traders Union
-5.45% for NuCana stock — technical signals warn of limited upside potential - Traders Union
Here’s why NuCana is sliding (January 26) - Traders Union
NuCana is falling today: what traders are watching (January 9) - Traders Union
NuCana stock price forecast: Sellers remain in control as NCNA edges toward support - Traders Union
NuCana stock drops 2.16% as sellers dominate below key moving averages - Traders Union
NuCana stock price forecast: rangebound days expected as NCNA holds steady near resistance - Traders Union
NuCana Appoints Theresa Bruce as Chief Operating Officer - GlobeNewswire Inc.
NuCana appoints Theresa Bruce as chief operating officer - Investing.com
NuCana (NASDAQ:NCNA) Trading Up 1.6% – Here’s Why - Defense World
NuCana plc ADR (NCNA) Stock Price Prediction for 2026, 2030-2040 - Traders Union
NuCana plc ADR (NCNA) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
NuCana reports partial responses in melanoma treatment trial - Investing.com
NuCana stock rises after securing key patent in China for cancer drug - Investing.com
Taking the lead: NuCana plc ADR (NCNA) - Setenews
NuCana compliant with all Nasdaq continued listing criteria - MSN
Rising Momentum in European ADRs: A Strategic Entry Point for US Investors - AInvest
NuCana regains Nasdaq compliance, extends cash runway into 2029 - Investing.com
Wall Street Today: Dow, Nasdaq, S&P 500 open flat as investors focus on China tariff deadline; Nvidia down 1.3% - Mint
NuCana plc Announces Change in American Depository Shares Ratio to Enhance Liquidity and Nasdaq Compliance - Quiver Quantitative
NuCana Cancels Series A Warrants Post-ATM Execution - The Globe and Mail
NuCana completes cancellation of all remaining Series A Warrants - Investing.com
NuCana Announces ADS Ratio Change to Enhance Liquidity - The Globe and Mail
NuCana to implement 1:200 reverse ADS split to boost share price - Investing.com
NuCana (NCNA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
NCNA Gets Second Nasdaq Notice; Hearing to Delay Potential Delisting - Stock Titan
NuCana enters $100 million at-the-market sales agreement for ADS offering - Investing.com
NuCana CEO takes leave of absence due to health reasons - Investing.com
nucana plc announces annual report release and upcoming agm - Investing.com
NuCana's Melanoma Breakthrough: Key Drug Advances to Expansion Trial, Q1 Losses Drop 63% Year-over-Year - Stock Titan
NuCana prices $7 million direct offering of ADSs and warrants - Investing.com
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? - Zacks Investment Research
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Yahoo Finance
NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NCNANuCana plc ADR Earnings - Finviz
Nucana Plc Adr Stock (NCNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):